Fremanezumab: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== | {{Short description|Monoclonal antibody for migraine prevention}} | ||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 458271234 | |||
| image = AJOVY.jpg | |||
| image2 = | |||
| tradename = Ajovy | |||
| synonyms = TEV-48125 | |||
| class = Monoclonal antibody | |||
}} | |||
'''Fremanezumab''', sold under the brand name '''Ajovy''', is a [[monoclonal antibody]] used for the prevention of [[migraine]]s. It is specifically designed to target and inhibit the activity of the [[calcitonin gene-related peptide]] (CGRP), a molecule involved in migraine pathophysiology. | |||
==Mechanism of Action== | |||
== Mechanism of Action == | |||
Fremanezumab works by binding to the CGRP ligand, thereby preventing it from interacting with its receptor. CGRP is a neuropeptide that plays a crucial role in the transmission of pain and the development of migraine headaches. By inhibiting CGRP, fremanezumab reduces the frequency and severity of migraine attacks. | Fremanezumab works by binding to the CGRP ligand, thereby preventing it from interacting with its receptor. CGRP is a neuropeptide that plays a crucial role in the transmission of pain and the development of migraine headaches. By inhibiting CGRP, fremanezumab reduces the frequency and severity of migraine attacks. | ||
== | ==Clinical Use== | ||
Fremanezumab is administered via subcutaneous injection | Fremanezumab is indicated for the preventive treatment of migraine in adults. It is administered via subcutaneous injection and can be given either as a monthly dose or a quarterly dose, depending on the patient's needs and the prescribing physician's recommendation. | ||
== Side Effects == | ==Side Effects== | ||
Common side effects of fremanezumab include injection site reactions, such as pain, redness, and swelling. Some patients may experience hypersensitivity reactions. It is important for | Common side effects of fremanezumab include injection site reactions, such as pain, redness, and swelling. Some patients may also experience hypersensitivity reactions. It is important for patients to discuss any adverse effects with their healthcare provider. | ||
== Development and Approval == | ==Development and Approval== | ||
Fremanezumab was developed by [[Teva Pharmaceuticals]] | Fremanezumab was developed by [[Teva Pharmaceuticals]] and received approval from the [[U.S. Food and Drug Administration]] (FDA) in September 2018. It was one of the first CGRP inhibitors to be approved for migraine prevention, marking a significant advancement in the treatment of this condition. | ||
== Related Pages == | ==Related Pages== | ||
* [[Migraine]] | * [[Migraine]] | ||
* [[Monoclonal antibody]] | * [[Monoclonal antibody]] | ||
| Line 27: | Line 31: | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category: | [[Category:Antimigraine drugs]] | ||
[[Category: | [[Category:Teva Pharmaceuticals products]] | ||
Latest revision as of 17:01, 5 March 2025
Monoclonal antibody for migraine prevention
| Fremanezumab | |
|---|---|
| |
| INN | |
| Drug class | Monoclonal antibody |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Fremanezumab, sold under the brand name Ajovy, is a monoclonal antibody used for the prevention of migraines. It is specifically designed to target and inhibit the activity of the calcitonin gene-related peptide (CGRP), a molecule involved in migraine pathophysiology.
Mechanism of Action[edit]
Fremanezumab works by binding to the CGRP ligand, thereby preventing it from interacting with its receptor. CGRP is a neuropeptide that plays a crucial role in the transmission of pain and the development of migraine headaches. By inhibiting CGRP, fremanezumab reduces the frequency and severity of migraine attacks.
Clinical Use[edit]
Fremanezumab is indicated for the preventive treatment of migraine in adults. It is administered via subcutaneous injection and can be given either as a monthly dose or a quarterly dose, depending on the patient's needs and the prescribing physician's recommendation.
Side Effects[edit]
Common side effects of fremanezumab include injection site reactions, such as pain, redness, and swelling. Some patients may also experience hypersensitivity reactions. It is important for patients to discuss any adverse effects with their healthcare provider.
Development and Approval[edit]
Fremanezumab was developed by Teva Pharmaceuticals and received approval from the U.S. Food and Drug Administration (FDA) in September 2018. It was one of the first CGRP inhibitors to be approved for migraine prevention, marking a significant advancement in the treatment of this condition.
